AN2 THERAPEUTICS, INC - DEVELOPMENT OF EPETRABOROLE AS A NOVEL THERAPEUTIC FOR MELIOIDOSIS AND ADDITIONAL ANTIMICROBIAL RESISTANT (AMR) BACTERIAL BIOTHREAT PATHOGENS.

On Nov 26, 2025, Department of Health and Human Services obligated $9,235,577 to AN2 THERAPEUTICS, INC for development of epetraborole as a novel therapeutic for melioidosis and additional antimicrobial resistant (amr) bacterial biothreat pathogens.. The award is classified under NAICS 541715 — RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) and issued as a cost no fee contract. Competition extent: full and open competition with 30 offers received. The procurement used a NO SET ASIDE USED. set-aside. Performance is located in MENLO PARK, CA. The contract is scheduled through Sep 30, 2026 — approximately 5 months remaining. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541715 — related awards are listed below.